Although the tumor-suppressive role of AKT3-174aa prevents its druggable potential, we think that the low expression of AKT3-174aa may allow for AKT be easily exposed to p-PDK1 or SETDB1 in GBM, and this makes AKT more sensitive to activation cascades. This evidence concerns the gene SETDB1 and glioblastoma.